This research agreement is to test and determine the effect of AAGP on monoclonal antibody production and bone marrow recovery.
UBC's antibody lab will test whether AAGP enhances the production of monoclonal antibodies from cell lines, an important manufacturing issue for current immunotherapies.
UBC will also test whether AAGP enhances the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy.
The goal will be to determine whether AAGP enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation.
ProtoKinetix has developed and patented a family of hyper stable, potent glycopeptides that enhance both engraftment and protection of transplanted cells used in regenerative medicine. The University of Alberta has begun Phase 1 human clinical trials.
Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date including diabetes, retinal degeneration, cardiac repair, and other degenerative conditions.
In addition, The company is studying the potential impact on several cancer therapies.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients